Amedisys — Q2 2024 Earnings Presentation
16 slides from Amedisys's earnings presentation, Jul 24, 2024
Slide 1: Amedisys Second Quarter 2024 Earnings Release Supplemental Slides
1 Amedisys Second Quarter 2024 Earnings Release Supplemental Slides July 24th, 2024 EXHIBIT 99.2
Slide 2: Forward-Looking Statements
2 This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could c
Slide 3: Our Key Areas of Focus
3 OUR KEY AREAS OF FOCUS Strategic areas of focus and progress made during Q2’24 • Home Health: Total same store admissions +13% • Hospice: Total same store ADC +0.4% • High Acuity Care: Admissions +56% 1 Organic Growth • Quality: Amedisys Jul’24 STARS score of 4.32 • 92% of care centers at 4+ Stars
Slide 4: Highlights and Summary Financial Results (Adjusted): 2Q 24
4 HIGHLIGHTS AND SUMMARY FINANCIAL RESULTS (ADJUSTED): 2Q 2024(1) EBITDA decreased $1 million over prior year on a $38 million increase in revenue. Excluding the impact of lower gains on the sale of fleet vehicles and a legal settlement, our EBITDA increased $3 million due to rate increases, home he
Slide 5: Revenue Mix and Reimbursement by Payor
5 57.3% 12.9% 29.8% Home Health Revenue Medicare FFS Private Episodic Per Visit & Case Rate 63.8% 34.5% 1.7% Amedisys Consolidated Revenue Home Health Hospice High Acuity Care • Medicare FFS: Reimbursed for a 30-day period of care • Private Episodic: MA and Commercial plans who reimburse us for a 30
Slide 6: Home Health and Hospice Segment (Adjusted) – Q2 2024
6 HOME HEALTH AND HOSPICE SEGMENT (ADJUSTED) – Q2 2024(1) • Medicare revenue per episode up 1.0% primarily due to the rate increase effective 1/1/2024. • Y/Y Total CPV up $6.79 (+6.2%) primarily due to raises, wage inflation, an increase in new hire pay and higher health insurance costs. • EBITDA ma
Slide 7: General & Administrative Expenses – Adjusted
7 GENERAL & ADMINISTRATIVE EXPENSES – ADJUSTED (1,2) Notes: • Year over year total G&A as a percentage of revenue decreased 100 basis points • $7.3 million increase in total G&A is primarily due to planned wage increases, higher incentive compensation costs, an increase in our health insurance costs
Slide 8: Operational Excellence: Home Health Cost Per Visit (CPV)-Adjusted
8 $25.00 $50.00 $75.00 $100.00 $125.00 2Q23 1Q24 2Q24 Cost Per Visit (CPV) Salaries Contractors Benefits Transportation OPERATIONAL EXCELLENCE: HOME HEALTH COST PER VISIT (CPV)-ADJUSTED YOY Total CPV impacted by higher labor costs and health insurance costs. *Note: Direct comparison with industry co
Slide 9: Driving Top Line Growth
9 DRIVING TOP LINE GROWTH 3% 3% 5% 8% 9% 4% 4% 7% 10% 13% 0.0% 4.0% 8.0% 12.0% 16.0% 120,000 130,000 140,000 150,000 160,000 2Q23 3Q23 4Q23 1Q24 2Q24 Volume SS Volume Growth SS Admit Growth Home Health Growth Hospice Growth -2% -2% -0.2% 0.3% 0.4% -3.0% -2.0% -1.0% 0.0% 1.0% 12,600 12,700 12,800 12,
Slide 10: Industry Leading Quality Scores
10 INDUSTRY LEADING QUALITY SCORES Quality of Patient Care (QPC) Patient Satisfaction (PS) • Amedisys maintains a 4-Star average in the Jul 2024 HHC Final release with 93% of our providers (representing 92% of care centers) at 4+ Stars and 59% of our providers (representing 60% of care centers) at 4
Slide 11: Hospice Quality: Moving Towards Best-in-Class
11 HOSPICE QUALITY: AMEDISYS HOSPICE CONTINUES TO MOVE TOWARDS BEST-IN-CLASS Hospice Quality Notes: Included in the above analysis are only active providers. EXHIBIT 99.2
Slide 12: Debt and Liquidity Metrics
12 DEBT AND LIQUIDITY METRICS Net leverage ~1.0x 1. Net debt defined as total debt outstanding ($391.2M) less cash and cash equivalents ($149.9M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($247.6M). 3. Liquidity defined as the sum of cash balance a
Slide 13: Cash Flow Statement Highlights
13 CASH FLOW STATEMENT HIGHLIGHTS (1) Total cash flow from operations for Q2-24 positively impacted by the collection of accounts receivable balances that were impacted by the Change Healthcare outage in Q1. 1. Free cash flow defined as cash flow from operations less routine capital expenditures and
Slide 14: Income Statement Adjustments
14 INCOME STATEMENT ADJUSTMENTS (1) 1. The financial results for the three-month periods ended June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024 and June 30, 2024 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GA
Slide 15: Environmental, Social, Governance (E.S.G.) Considerations
15 Environmental, Social, Governance (E.S.G.) Considerations EXHIBIT 99.2
Slide 16: Environmental, Social, Governance (E.S.G.) Considerations
16 ENVIRONMENTAL, SOCIAL, GOVERNANCE (E.S.G.) CONSIDERATIONS Sustainable, high-quality, patient focused, home-based care model E n vi ro nmental, Social, Govern an ce Environmental • Amedisys is dedicated to the sustainability of our business and the communities in which we serve • Environmental hea